The Effects of Combination Anti-HIV Medication on Human Papillomavirus (HPV) in HIV-Infected Women

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Overall Status
Completed
CT.gov ID
NCT00006444
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (NIH)
160
51
57
3.1
0.1

Study Details

Study Description

Brief Summary

The purpose of this study is to see how often human papillomavirus (HPV) occurs in HIV-infected women who have not taken anti-HIV drugs and to learn whether taking anti-HIV drugs will affect HPV in women.

HIV infection increases the risk of getting HPV infection. Findings suggest that HIV infection as well as a weakened immune system may increase the chances of getting HPV. Aggressive anti-HIV medication has been shown to strengthen the immune system. Researchers want to learn whether anti-HIV drugs affect the HPV virus or decrease the chances of getting HPV. This study is important because it may provide important information to help manage a woman's health and to determine a woman's risk for developing problems with the cervix (outer end of the uterus).

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    HIV infection is a significant risk factor for human HPV infection and the development of HPV-associated lesions in the female genital tract. Findings suggest that HIV infection and/or HIV-related immunosuppression increases a woman's susceptibility to HPV infection or alters the natural history of preexisting HPV infection. Treatment with HAART has been shown to result in significant increases in CD4+ cell counts and "partial reconstitution" of the immune system. It is not known whether treatment of HIV infection with potent antiretroviral regimens could affect the persistence of HPV infection and progression of cervical dysplasia. This study is important for HIV-infected women because of the implications for gynecologic management and determination of cervical disease risk.

    At baseline, Weeks 24 and 48, and then every 48 weeks until study completion, women undergo pelvic examination and cervical specimens collection by the following methods: 1) Sno-strip; 2) cervicovaginal lavage; 3) cervical brush method; and 4) Pap smear. A colposcopy is required for any woman who has an abnormal Pap smear reading unless the abnormal Pap smear is thought to be due to an intercurrent infection. A cervical biopsy is strongly recommended in the event of an abnormal colposcopy. Blood is collected for HPV antibody testing, viral load, and CD4 measures.

    Study Design

    Study Type:
    Observational
    Official Title:
    Assessment of Prevalence and Persistence of Human Papillomavirus (HPV) DNA in HIV-Infected Women Who Are Antiretroviral Naive and Have Initiated HAART
    Study Start Date :
    Nov 1, 2000
    Actual Study Completion Date :
    Aug 1, 2005

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      13 Years and Older
      Sexes Eligible for Study:
      Female
      Accepts Healthy Volunteers:
      No

      Inclusion Criteria

      Women may be eligible for this study if they:
      • Are HIV-positive.

      • Are at least 13 years of age and menstruating.

      • Are willing to enroll in another drug study.

      • Have written consent of a parent or guardian if under 18 years.

      • This study has been changed to increase enrollment. Women who are starting HAART-based therapy prescribed by a personal physician or participating in an antiretroviral trial are all eligible.

      • Intend to start antiretroviral therapy within 14 days of study entry.

      Exclusion Criteria

      Women will not be eligible for this study if they:
      • Have been on anti-HIV treatment for more than 14 days.

      • Are abusing drugs or alcohol.

      • Are receiving medication that affects the immune system, fights HPV, or is investigational, except for anti-HIV drugs provided by coenrolling in a Phase II or III trial with approval of a study chair within 30 days of study entry, including but not limited to systemic interferons and interleukins, thalidomide, systemic cidofovir, and HPV vaccines. This study has been changed. The following medications are no longer excluded: thymopentin, hydroxyurea, granulocyte colony-stimulating factor (G-CSF and filgrastim), and GM-CSF (sargramostim).

      • Have cervical cancer or a history of cervical cancer.

      • Have had a hysterectomy (removal of the uterus).

      • Participated in HPV trials at any time.

      • Use imiquimod inside the vagina.

      • Are taking corticosteroid treatment in large doses.

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Univ of Alabama at Birmingham Birmingham Alabama United States 35294
      2 Children's Hosp of Los Angeles/UCLA Med Ctr Los Angeles California United States 900276016
      3 Univ of Southern California / LA County USC Med Ctr Los Angeles California United States 900331079
      4 Los Angeles County - USC Med Ctr Los Angeles California United States 90033
      5 UCLA CARE Ctr Los Angeles California United States 90095
      6 Univ of California, San Diego San Diego California United States 92103
      7 University of California San Francisco San Francisco California United States 941104206
      8 San Mateo County AIDS Program Stanford California United States 94305-5107
      9 Stanford Univ Stanford California United States 94305-5107
      10 Willow Clinic Stanford California United States 94305-5107
      11 Univ of Colorado Health Sciences Ctr, Denver Denver Colorado United States 80262-3706
      12 Howard Univ Hosp Washington District of Columbia United States 20060
      13 North Broward Hosp District Fort Lauderdale Florida United States 33311
      14 Univ of Florida Health Science Ctr / Pediatrics Jacksonville Florida United States 32209
      15 Univ of Miami School of Medicine Miami Florida United States 331361013
      16 Univ of Miami / Jackson Memorial Hosp Miami Florida United States 33136
      17 Univ of Miami (Pediatric) Miami Florida United States 33161
      18 Emory Univ Atlanta Georgia United States 30308
      19 Univ of Hawaii Honolulu Hawaii United States 96816
      20 Mt Sinai Hosp Med Ctr / Dept of Pediatrics Chicago Illinois United States 60608
      21 Northwestern Univ Med School Chicago Illinois United States 60611
      22 The CORE Ctr Chicago Illinois United States 60612
      23 Indiana Univ Hosp Indianapolis Indiana United States 462025250
      24 Methodist Hosp of Indiana / Life Care Clinic Indianapolis Indiana United States 46202
      25 Wishard Hosp Indianapolis Indiana United States 46202
      26 Univ of Maryland (Pediatric) Baltimore Maryland United States 20201
      27 Univ of Maryland, Institute of Human Virology Baltimore Maryland United States 21201
      28 Johns Hopkins Hosp Baltimore Maryland United States 21287
      29 Boston Med Ctr (Harvard) Boston Massachusetts United States 02118
      30 Boston Med Ctr (Pediatric) Boston Massachusetts United States 02118
      31 Beth Israel Deaconess - West Campus Boston Massachusetts United States 02215
      32 Brigham and Women's Hosp Boston Massachusetts United States 02215
      33 Montefiore Med Ctr Adolescent AIDS Program Bronx New York United States 10467
      34 Beth Israel Med Ctr New York New York United States 10003
      35 Bellevue Hosp / New York Univ Med Ctr New York New York United States 10016
      36 Columbia Presbyterian Med Ctr New York New York United States 10032
      37 Community Health Network Rochester New York United States 14642-001
      38 Univ of Rochester Medical Center Rochester New York United States 14642
      39 State Univ of New York at Stony Brook Stony Brook New York United States 117948111
      40 Univ of North Carolina Chapel Hill North Carolina United States 275997215
      41 Duke Univ Med Ctr Durham North Carolina United States 27710
      42 Case Western Reserve Univ Cleveland Ohio United States 44106
      43 MetroHealth Med Ctr Cleveland Ohio United States 441091998
      44 Univ of Pittsburgh Pittsburgh Pennsylvania United States 15213
      45 Brown Univ / Miriam Hosp Providence Rhode Island United States 02906
      46 Brown Univ / The Miriam Hosp Providence Rhode Island United States 02906
      47 Miriam Hosp / Brown Univ Providence Rhode Island United States 02906
      48 Julio Arroyo West Columbia South Carolina United States 29169
      49 University of Washington (Seattle) Seattle Washington United States 98104
      50 Univ of Puerto Rico / Univ Children's Hosp AIDS San Juan Puerto Rico 009365067
      51 San Juan City Hosp San Juan Puerto Rico 009367344

      Sponsors and Collaborators

      • National Institute of Allergy and Infectious Diseases (NIAID)
      • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

      Investigators

      • Study Chair: Kathleen Squires,
      • Study Chair: Rebecca Clark,
      • Study Chair: Kenneth H Fife,

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      , ,
      ClinicalTrials.gov Identifier:
      NCT00006444
      Other Study ID Numbers:
      • A5029
      • AACTG A5029
      • ACTG A5029
      First Posted:
      Aug 31, 2001
      Last Update Posted:
      Nov 20, 2013
      Last Verified:
      Nov 1, 2013
      Keywords provided by , ,
      Additional relevant MeSH terms:

      Study Results

      No Results Posted as of Nov 20, 2013